Pharmaceutical Preparations
Standard Industrial Classification: SIC 2834
Industry Insider Sentiment Analysis
The Pharmaceutical Preparations sector (SIC 2834) acts as a critical barometer for broader economic health. Our real-time monitoring reveals total transactions. Monitoring "cluster buying" is one of the most reliable leading indicators for future sector performance. By analyzing aggregate data across this specific Standard Industrial Classification, investors can filter out individual company volatility and identify high-conviction trends. When multiple directors and officers within the same industry move capital simultaneously, it often signals an upcoming sector-wide revaluation or a fundamental shift in supply chain dynamics that has yet to be recognized by the broader public market.
| Filing Date | Trade Date | Ticker | Company | Reporting Person | Relationship | Type | Price | Qty | Total, $ | Owned After |
|---|---|---|---|---|---|---|---|---|---|---|
| 2026-03-04 00:15 | 2026-03-02 | AGIO | Agios Pharmaceuticals Inc. | Gheuens Sarah | Officer | OPT+S | $28.96 | 4,055 | $117,433 | 74,406 |
| 2026-03-04 00:14 | 2026-03-02 | AGIO | Agios Pharmaceuticals Inc. | Jones Cecilia | Officer | OPT+S | $28.96 | 5,035 | $145,814 | 49,328 |
| 2026-03-04 00:13 | 2026-03-02 | AGIO | Agios Pharmaceuticals Inc. | Milanova Tsveta | Officer | OPT+S | $28.96 | 2,868 | $83,057 | 41,591 |
| 2026-03-04 00:12 | 2026-03-02 | AGIO | Agios Pharmaceuticals Inc. | Washburn Theodore James Jr. | Officer | OPT+S | $28.96 | 2,223 | $64,378 | 6,140 |
| 2026-03-04 01:03 | 2026-02-27 | NGNE | Neurogene Inc. | Cvijic Christine Mikail | Officer | SELL | $25.11 | 4,800 | $120,526 | 109,843 |
| 2026-03-04 00:05 | 2026-02-27 | HROW | HARROW, INC. | Opaleye Management Inc. | 10% owner | SELL | $54.18 | 5,000 | $270,900 | 65,000 |
| 2026-03-04 00:46 | 2026-03-02 | BIOA | BioAge Labs, Inc. | RUBIN PAUL D | Officer | OPT+S | $20.30 | 7,433 | $150,890 | 0 |
| 2026-03-04 00:01 | 2026-03-02 | REGN | REGENERON PHARMACEUTICALS, INC. | RYAN ARTHUR F | Director | SELL | $785.50 | 100 | $78,550 | 17,703 |
| 2026-03-04 01:35 | 2026-02-27 | AUPH | Aurinia Pharmaceuticals Inc. | TANG KEVIN | Director | BUY | $14.10 | 900,000 | $12,688,830 | 12,229,500 |
| 2026-03-04 00:31 | 2026-03-03 | UTHR | UNITED THERAPEUTICS Corp | MALCOLM JAN | Director | SELL | $509.20 | 50 | $25,460 | 170 |
| 2026-03-04 00:31 | 2026-03-02 | UTHR | UNITED THERAPEUTICS Corp | ROTHBLATT MARTINE A | Director, Officer | OPT+S | $515.37 | 9,500 | $4,896,019 | 130 |
| 2026-03-04 02:01 | 2026-03-03 | ANIP | Ani Pharmaceuticals Inc. | Walsh Patrick D | Director | SELL | $74.23 | 6,000 | $445,380 | 52,405 |
| 2026-03-04 05:31 | 2026-03-02 | SYRE | Spyre Therapeutics, Inc. | Turtle Cameron | Director, Officer | SELL | $42.19 | 15,000 | $632,867 | 642,540 |
| 2026-03-04 05:32 | 2026-03-03 | SYRE | Spyre Therapeutics, Inc. | Burrows Scott L | Officer | OPT+S | $40.65 | 2,500 | $101,620 | 97,994 |
| 2026-03-04 04:41 | 2026-03-02 | ARQT | Arcutis Biotherapeutics Inc. | Burnett Patrick | Officer | SELL | $25.18 | 6,287 | $158,320 | 121,150 |
| 2026-03-04 04:42 | 2026-03-02 | ARQT | Arcutis Biotherapeutics Inc. | Vairavan Latha | Officer | SELL | $25.18 | 2,853 | $71,844 | 87,754 |
| 2026-03-04 04:42 | 2026-02-27 | ARQT | Arcutis Biotherapeutics Inc. | Matsuda Masaru | Officer | SELL | $26.03 | 12,058 | $313,877 | 136,932 |
| 2026-03-04 04:42 | 2026-03-02 | ARQT | Arcutis Biotherapeutics Inc. | Watanabe Todd | Director, Officer | SELL | $25.18 | 37,349 | $940,526 | 785,957 |
| 2026-03-04 04:43 | 2026-03-02 | ARQT | Arcutis Biotherapeutics Inc. | Edwards Larry Todd | Officer | SELL | $25.18 | 3,687 | $92,846 | 175,178 |
| 2026-03-04 04:20 | 2026-03-02 | ABT | Abbott Laboratories | Shroff Eric | Officer | SELL | $115.58 | 709 | $81,946 | 39,164 |
| 2026-03-04 04:05 | 2026-03-02 | GNLX | GENELUX Corp | Thomas John | Director | SELL | $2.90 | 10,000 | $28,957 | 482,784 |
| 2026-03-04 04:06 | 2026-03-02 | ABT | Abbott Laboratories | Morrone Louis H. | Officer | SELL | $115.58 | 1,144 | $132,224 | 76,843 |
| 2026-03-04 04:10 | 2026-03-02 | ABT | Abbott Laboratories | Salvadori Daniel Gesua Sive | Officer | SELL | $115.58 | 885 | $102,288 | 146,377 |
| 2026-03-04 03:55 | 2026-03-02 | ABT | Abbott Laboratories | MCCOY JOHN A. JR. | Officer | SELL | $115.58 | 585 | $67,614 | 24,628 |
| 2026-03-04 03:39 | 2026-03-02 | ABT | Abbott Laboratories | Cushman Elizabeth C. | Officer | SELL | $115.58 | 263 | $30,398 | 38,573 |
| 2026-03-04 03:06 | 2026-03-02 | RARE | Ultragenyx Pharmaceutical Inc. | KAKKIS EMIL D | Director, Officer | SELL | $22.80 | 54,404 | $1,240,411 | 658,994 |
| 2026-03-04 03:08 | 2026-03-02 | RARE | Ultragenyx Pharmaceutical Inc. | Harris Erik | Officer | SELL | $22.80 | 10,539 | $240,289 | 89,515 |
| 2026-03-04 03:09 | 2026-03-02 | RARE | Ultragenyx Pharmaceutical Inc. | Pinion John Richard | Officer | SELL | $22.80 | 10,029 | $228,661 | 110,026 |
| 2026-03-04 02:10 | 2026-03-02 | ABBV | AbbVie Inc. | Siatis Perry C | Officer | SELL | $234.39 | 18,668 | $4,375,550 | 4,619 |
| 2026-03-04 00:25 | 2026-02-27 | VRTX | VERTEX PHARMACEUTICALS INC / MA | Bozic Carmen | Officer | SELL | $480.31 | 2,329 | $1,118,642 | 37,734 |
| 2026-03-04 00:25 | 2026-03-02 | KPTI | Karyopharm Therapeutics Inc. | Rangwala Reshma | Officer | SELL | $9.41 | 5,066 | $47,669 | 56,739 |
| 2026-03-03 16:00 | 2026-03-02 | FBLG | FibroBiologics, Inc. | Davis Jason | Officer | BUY | $0.41 | 70,000 | $28,973 | 70,000 |
| 2026-03-03 00:32 | 2026-02-26 | NUVL | Nuvalent, Inc. | Miller Deborah Ann | Officer | OPT+S | $103.05 | 5,500 | $566,788 | 59,634 |
| 2026-03-03 00:01 | 2026-02-26 | TEVA | TEVA PHARMACEUTICAL INDUSTRIES LTD | Kalif Eliyahu Sharon | Officer | SELL | $33.64 | 345,810 | $11,634,708 | 57,478 |
| 2026-03-03 00:30 | 2026-02-23 | OVID | Ovid Therapeutics Inc. | ALEXANDER MARGARET A. | Director, Officer | SELL | $1.45 | 11,656 | $16,901 | 61,750 |
| 2026-03-03 00:30 | 2026-02-27 | LRMR | Larimar Therapeutics, Inc. | Hamilton Thomas Edward | Director | BUY | $5.00 | 100,000 | $500,000 | 664,798 |
| 2026-03-03 00:30 | 2026-02-23 | OVID | Ovid Therapeutics Inc. | Rona Jeffrey A | Officer | SELL | $1.45 | 8,541 | $12,384 | 88,188 |
| 2026-03-03 00:30 | 2026-02-27 | LRMR | Larimar Therapeutics, Inc. | THOMAS FRANK E | Director | BUY | $5.00 | 5,000 | $25,000 | 7,000 |
| 2026-03-03 01:14 | 2026-02-26 | JAZZ | Jazz Pharmaceuticals plc | Carr Patricia | Officer | SELL | $192.60 | 2,370 | $456,466 | 9,235 |
| 2026-03-03 00:30 | 2026-02-27 | LRMR | Larimar Therapeutics, Inc. | SHERMAN JEFFREY W | Director | BUY | $5.00 | 5,000 | $25,000 | 5,000 |
| 2026-03-03 00:30 | 2026-02-27 | UTHR | UNITED THERAPEUTICS Corp | Olian Judy D. | Director | SELL | $509.55 | 200 | $101,910 | 4,845 |
| 2026-03-03 00:29 | 2026-03-02 | CYTK | CYTOKINETICS INC | PARSHALL B LYNNE | Director | SELL | $61.21 | 5,000 | $306,050 | 17,933 |
| 2026-03-03 00:28 | 2026-03-02 | CYTK | CYTOKINETICS INC | Callos Andrew | Officer | OPT+S | $61.62 | 886 | $54,595 | 50,440 |
| 2026-03-03 04:57 | 2026-02-27 | ARVN | Arvinas Inc. | Houston John G | Director | SELL | $13.21 | 35,297 | $466,153 | 1,122,183 |
| 2026-03-03 03:46 | 2026-02-27 | LRMR | Larimar Therapeutics, Inc. | Flynn James E | Director, 10% owner | BUY | $5.00 | 5,000,000 | $25,000,000 | 6,207,982 |
| 2026-03-03 03:18 | 2026-03-02 | IDYA | IDEAYA Biosciences, Inc. | Stein Jeffrey | Director | BUY | $32.96 | 50,000 | $1,647,890 | 54,281 |
| 2026-03-03 03:05 | 2026-03-02 | NRIX | Nurix Therapeutics, Inc. | Ring Christine | Officer | SELL | $15.44 | 8,148 | $125,793 | 34,601 |
| 2026-03-03 02:44 | 2026-02-26 | LFVN | Lifevantage Corp | Dayton Judd | Director | BUY | $4.59 | 33,197 | $152,421 | 80,359 |
| 2026-03-03 02:47 | 2026-03-02 | ORKA | Oruka Therapeutics, Inc. | Sandler Laura Lee | Officer | OPT+S | $33.56 | 5,000 | $167,822 | 237,584 |
| 2026-03-03 02:28 | 2026-03-02 | CTNM | Contineum Therapeutics, Inc. | Watkins Tim | Officer | OPT+S | $15.02 | 3,611 | $54,220 | 0 |
Sector-Wide Insider Alpha
Analyzing insider movements across the Pharmaceutical Preparations sector provides a macro-view of executive conviction. When multiple leaders in different companies within the same SIC code (2834) simultaneously buy shares, it often indicates an industry-wide undervaluation or a positive shift in market cycles.
SEC Filings in Pharmaceutical Preparations
Every transaction in the Pharmaceutical Preparations industry is reported via Form 4 disclosures. By filtering these filings by industry, investors can detect institutional-scale sentiment shifts before they are reflected in broader market indices, following the capital flow of those with intimate industry knowledge.
UNDERSTANDING THE DATA
FILING DATE: The date and time when the transaction was reported to the SEC. This is when the public first receives the information.
TRADE DATE: The actual day the insider executed the purchase or sale in the market.
INDUSTRY: The specific market sector the company operates in. Useful for identifying broader institutional capital flows across sectors.
OWNED AFTER: The total number of shares held by the insider following the transaction. This highlights the insider's remaining conviction in the company.
CHANGE %: The percentage increase or decrease of the insider's total position. Large percentage changes often carry more weight than the dollar amount alone.
TRADE TYPES DEFINITIONS
BUY: An open market purchase. Typically indicates an insider's belief that the stock is undervalued or poised for growth.
SELL: An open market sale. While often used for diversification or liquidity, large or unexpected sales can be a warning signal.
OPT+S (OPTION EXERCISE & SALE): This occurs when an insider exercises their stock options and sells them immediately. Often part of a structured compensation plan.